Figure 2.
Figure 2. Role of RANTES oligomerization in RANTES-induced transendothelial migration of monocytes. (A-B) Monocytes were subjected to chemotaxis assays across bare filters (A) or across resting HMVECs (B) for 90 minutes with RANTES or indicated RANTES mutants (1 nM) in the lower chamber. Transmigrated cells were counted by flow cytometry and expressed as chemotactic index (percent of control). Transendothelial chemotaxis of monocytes was reduced by pretreatment with the CCR5 antagonist TAK-779 or with the CCR1 antagonist BX471 to 34% ± 28% and 45% ± 19% of control, respectively. (C) Dose dependence of monocyte transendothelial chemotaxis in response to RANTES or mutants at indicated concentrations. Transmigrated cells were counted by flow cytometry and expressed as chemotactic index. Data represent mean ± SD of 4 to 6 separate experiments. *P < .05 versus wild-type RANTES (nonparametric signed-rank tests).

Role of RANTES oligomerization in RANTES-induced transendothelial migration of monocytes. (A-B) Monocytes were subjected to chemotaxis assays across bare filters (A) or across resting HMVECs (B) for 90 minutes with RANTES or indicated RANTES mutants (1 nM) in the lower chamber. Transmigrated cells were counted by flow cytometry and expressed as chemotactic index (percent of control). Transendothelial chemotaxis of monocytes was reduced by pretreatment with the CCR5 antagonist TAK-779 or with the CCR1 antagonist BX471 to 34% ± 28% and 45% ± 19% of control, respectively. (C) Dose dependence of monocyte transendothelial chemotaxis in response to RANTES or mutants at indicated concentrations. Transmigrated cells were counted by flow cytometry and expressed as chemotactic index. Data represent mean ± SD of 4 to 6 separate experiments. *P < .05 versus wild-type RANTES (nonparametric signed-rank tests).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal